Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1088 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Apert Syndrome | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Included Tests | ||||||||||||||||||||||||||||||
| FGFR2 Exon 8 only | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 1 to 2 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Sanger Sequencing | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
The craniosynostosis syndromes are a group of disorders sharing the premature fusion of one or more sutures of the skull. Often additional anomalies are associated. There are eight craniosynostosis disorders caused by mutations in three fibroblast growth factor receptor genes: FGFR1, FGFR2 and FGFR3. All are autosomal dominant. Penetrance varies with the specific craniosynostosis type. Many FGFR mutations are associated with advanced paternal age. Apert syndrome (MIM 101200) is a relatively severe form of FGFR2 related craniosynostosis with numerous organ systems being affected. Findings in Apert syndrome include turribrachycephalic skull shape a wide open anterior fontanelle at birth, broad thumbs and great toes that deviate away from the other digits, variable syndactyly of hands and feet, but involving at least the central 3 digits of the hands, incomplete postaxial polydactyly of the hands and preaxial polydactyly of the feet, progressive synostosis of the cervical vertebrae, and bones of the hands and feet. Typical FGFR related craniosynostosis findings include midface hypoplasia, mandibular prognathism, cleft palate, small beaked nose, hypertelorism, ocular proptosis and other ocular abnormalities. Central nervous system abnormalities with variable degrees of intellectual disability occur in 50% of patients. Cutaneous manifestations include acne, hyperhidrosis, hyperkeratosis and hypopigmentation among others. The majority of cases are sporadic and the prevelance is 1:65,000 to 1:100,000. Penetrance is complete. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| FGFR2 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 101200 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Craniosynostosis and Craniofacial Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.